Kymera Therapeutics (NASDAQ:KYMR) Research Coverage Started at Jefferies Financial Group

Jefferies Financial Group started coverage on shares of Kymera Therapeutics (NASDAQ:KYMR) in a research report sent to investors on Monday, MarketBeat reports. The firm issued a buy rating and a $110.00 price target on the stock.

A number of other equities analysts have also recently weighed in on the company. B. Riley Financial boosted their price target on Kymera Therapeutics from $80.00 to $117.00 and gave the stock a “buy” rating in a report on Monday, December 22nd. JPMorgan Chase & Co. lifted their price objective on Kymera Therapeutics from $70.00 to $125.00 and gave the stock an “overweight” rating in a research report on Wednesday, December 10th. Weiss Ratings reissued a “sell (d-)” rating on shares of Kymera Therapeutics in a research note on Thursday, January 22nd. Leerink Partners upped their target price on shares of Kymera Therapeutics from $70.00 to $118.00 and gave the company an “outperform” rating in a report on Monday, December 8th. Finally, Wells Fargo & Company raised their price target on shares of Kymera Therapeutics from $69.00 to $116.00 and gave the stock an “overweight” rating in a research note on Tuesday, December 9th. One investment analyst has rated the stock with a Strong Buy rating, twenty have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Kymera Therapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $118.90.

Kymera Therapeutics Price Performance

KYMR stock opened at $79.14 on Monday. The company’s 50 day simple moving average is $79.56 and its 200-day simple moving average is $69.12. Kymera Therapeutics has a 12 month low of $19.44 and a 12 month high of $103.00. The firm has a market capitalization of $6.46 billion, a PE ratio of -21.51 and a beta of 2.20.

Kymera Therapeutics (NASDAQ:KYMR) last issued its quarterly earnings data on Thursday, February 26th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.77) by ($0.20). Kymera Therapeutics had a negative return on equity of 28.71% and a negative net margin of 794.04%.The company had revenue of $2.87 million for the quarter, compared to analyst estimates of $14.80 million. During the same quarter in the prior year, the firm earned ($0.88) earnings per share. The company’s revenue for the quarter was down 60.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Kymera Therapeutics will post -2.79 earnings per share for the current year.

Insider Transactions at Kymera Therapeutics

In related news, CFO Bruce N. Jacobs sold 7,576 shares of the stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $88.93, for a total transaction of $673,733.68. Following the transaction, the chief financial officer directly owned 237,483 shares in the company, valued at approximately $21,119,363.19. This represents a 3.09% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, insider Jared Gollob sold 5,613 shares of the firm’s stock in a transaction dated Monday, March 2nd. The stock was sold at an average price of $88.93, for a total value of $499,164.09. Following the completion of the sale, the insider directly owned 122,029 shares in the company, valued at approximately $10,852,038.97. The trade was a 4.40% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 196,561 shares of company stock valued at $17,097,428. Corporate insiders own 16.01% of the company’s stock.

Institutional Investors Weigh In On Kymera Therapeutics

Institutional investors have recently bought and sold shares of the stock. US Bancorp DE boosted its holdings in shares of Kymera Therapeutics by 9.8% in the 3rd quarter. US Bancorp DE now owns 1,865 shares of the company’s stock valued at $106,000 after purchasing an additional 166 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. increased its holdings in shares of Kymera Therapeutics by 9.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,764 shares of the company’s stock worth $156,000 after buying an additional 248 shares during the last quarter. Larson Financial Group LLC increased its holdings in shares of Kymera Therapeutics by 36.9% during the 4th quarter. Larson Financial Group LLC now owns 1,064 shares of the company’s stock worth $83,000 after buying an additional 287 shares during the last quarter. State Board of Administration of Florida Retirement System raised its position in shares of Kymera Therapeutics by 3.3% in the 4th quarter. State Board of Administration of Florida Retirement System now owns 12,655 shares of the company’s stock worth $985,000 after buying an additional 410 shares during the period. Finally, Smartleaf Asset Management LLC raised its position in shares of Kymera Therapeutics by 382.0% in the 4th quarter. Smartleaf Asset Management LLC now owns 535 shares of the company’s stock worth $42,000 after buying an additional 424 shares during the period.

Kymera Therapeutics Company Profile

Kymera Therapeutics, Inc is a clinical‐stage biopharmaceutical company headquartered in Watertown, Massachusetts, focused on the discovery, development and commercialization of small‐molecule therapies that harness the body’s natural protein homeostasis pathways. Since its founding in 2016, Kymera has pursued a targeted protein degradation platform designed to identify and selectively eliminate disease‐causing proteins. The company’s proprietary Pegasus™ platform integrates insights from ubiquitin biology and medicinal chemistry to advance novel degrader candidates across a range of therapeutic areas.

The company’s pipeline emphasizes immunology and oncology.